Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats

Acta Pharmacologica Sinica

Volumn 33, Issue 4, 2012, Pages 459-469

  Ivanová, Monika ^a   Dovinová, Ima ^a   Okruhlicová, L'Udmila ^a   Tribulová, Narcisa ^a   Šimončíková, Petra ^a   Barte Ková, Monika ^a   Vlkovičová, Jana ^a   Barančík, Miroslav ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Akt kinase; cardiotoxicity; doxorubicin; heart; matrix metalloproteinases; reactive oxygen species

Indexed keywords

CASPASE 3; DOXORUBICIN; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CHEMOLUMINESCENCE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; EXTRACELLULAR SPACE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART RATE; HISTOPATHOLOGY; IMMUNOBLOTTING; MALE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TRANSMISSION ELECTRON MICROSCOPY; ZYMOGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CASPASE 3; DOXORUBICIN; ENZYME ACTIVATION; HEART; MALE; MATRIX METALLOPROTEINASES; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; SUPEROXIDES;

EID: 84859585326     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.194     Document Type: Article

References (32)

1. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987; 19: 817-28. (Pubitemid 17144746)
2. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009; 296: H1466-83.
3. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004; 91: 37-44. (Pubitemid 39013042)
4. Robert J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol 2007; 7: 135-9. (Pubitemid 47339860)
5. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-5. (Pubitemid 28446849)
6. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4. (Pubitemid 129519680)
7. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-9.
8. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005; 112: 544-52. (Pubitemid 41060795)
9. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003; 33: 648-56. (Pubitemid 36918626)
10. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002; 53: 165-74. (Pubitemid 34020777)
11. Bai P, Mabley JG, Liaudet L, Virag L, Szabo C, Pacher P. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep 2004; 11: 505-8.
12. Kurata H, Thant AA, Matsuo S, Senga T, Okazaki K, Hotta N, et al. Constitutive activation of MAP kinase kinase (MEK1) is critical and sufficient for the activation of MMP-2. Exp Cell Res 2000; 254: 180-8. (Pubitemid 30066744)
13. Spanikova A, Ivanova M, Matejikova J, Ravingerova T, Barancik M. Influence of ischemia/reperfusion and modulation of PI3K/Akt kinase pathway on matrix metalloproteinase-2 in rat hearts. Gen Physiol Biophys 2010; 29: 31-40.
14. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, et al. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 2006; 69: 736-45. (Pubitemid 43139736)
15. Guzik TJ, Channon KM. Measurement of vascular reactive oxygen species production by chemiluminiscence. Methods Mol Med 2005; 108: 73-89.
16. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 1999; 26: 1231-7. (Pubitemid 29262709)
17. Bradford M. A rapid and sensitive method for the quantitation of microgram quanties of protein utilizing the principle of protein-dyebinding. Anal Biochem 1976; 72: 248-54.
18. Šimončíková P, Ravingerová T, Barančík M. The effect of chronic doxorubicin treatment on mitogen-activated protein kinases and heat stress proteins in rat heart. Physiol Res 2008; 57: S97-101.
19. Adamcová M, Potacova A, Popelova O, Sterba M, Mazurova Y, Aupperle H, et al. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol Res 2010; 59: 831-6.
20. Kizaki K, Ito R, Okadaa M, Kazuki K, Uchide T, Temmac K, et al. Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res 2006; 53: 341-6.
21. Goetzenich A, Hatam N, Zernecke A, Weber C, Czarnotta T, Autschbach R, et al. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig. J Heart Lung Transplant 2009; 28: 1087-93.
22. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001; 276: 29596-602.
23. Deng S, Kruger A, Schmidt A, Metzger A, Yan T, Godtel-Armbrust U, et al. Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice. Naunyn Schmiedebergs Arch Pharmacol 2009; 380: 25-34.
24. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101: 1833-9. (Pubitemid 30213106)
25. Ichihara S, Yamada Y, Kawai Y, Osawa T, Furuhashi K, Duan Z, et al. Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity. Biochem Biophys Res Commun 2007; 359: 27-33. (Pubitemid 46836667)
26. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002; 62: 4592-8.
27. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448-60. (Pubitemid 38210151)
28. Das J, Ghosh J, Manna P, Sil PC. Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via upregulation of PI3-K/Akt and inhibition of p53, p38-JNK. Biochem Pharmacol 2011; 81: 891-909.
29. Bae IH, Park MJ, Yoon SH., Kang SW, Lee SS, Choi KM, et al. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase- 2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006; 66: 4991-5. (Pubitemid 43844917)
30. Lee SJ, Bae SS, Kim KH, Lee WS, Rhim BY, Hong KW, et al. High glucose enhances MMP-2 production in adventitial fibroblasts via Akt1-dependent NF-kappaB pathway. FEBS Lett 2007; 581: 4189-94. (Pubitemid 47301852)
31. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C, et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007; 50: 212-8. (Pubitemid 46986043)
32. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-31. (Pubitemid 351707391)